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ABSTRACT
Background and objective: Malignant pleural effusion
is associated with morbidity and mortality. A rando-
mized controlled trial previously compared clinical out-
comes and resource use with indwelling pleural
catheter (IPC) and talc pleurodesis in this population.
Using unpublished quality of life data, we estimate the
cost-effectiveness of IPC compared with talc
pleurodesis.
Methods: Healthcare utilization and costs were cap-
tured during the trial. Utility weights produced by the
EuroQol Group ﬁve-dimensional three-level question-
naire and survival were used to determine quality-
adjusted life-years (QALYs) gained. The incremental
cost-effectiveness ratio (ICER) was calculated over the
1-year trial period. Sensitivity analysis used patient sur-
vival data and modelled additional nursing time
required per week for catheter drainage.
Results: Utility scores, cost and QALYs gained did not
differ signiﬁcantly between groups. The ICER for IPC
compared with talc was favorable at $US10 870 per
QALY gained. IPC was less costly with a probability
exceeding 95% of being cost-effective when survival was
<14 weeks, and was more costly when 2-h nursing time
per week was assumed for catheter drainage.
Conclusion: IPC is cost-effective when compared with
talc, although substantial uncertainty exists around this
estimate. IPC appears most cost-effective in patients
with limited survival. If signiﬁcant nursing time is
required for catheter drainage, IPC becomes less likely
to be cost-effective. Either therapy may be considered
as a ﬁrst-line option in treating malignant pleural effu-
sion in patients without history of prior pleurodesis,
with consideration for patient survival, support and
preferences.
Clinical trial registration: ISRCTN87514420 at isrctn.com
Key words: chest tubes, cost-effectiveness analysis, palliative
care, pleural effusion malignant, pleurodesis.
Abbreviations: ECOG, Eastern Cooperative Oncology Group;
EORTC QLQ-C30, European Organization for Research and
Treatment of Cancer Quality of Life Questionnaire – Core
Questionnaire; EQ-5D-3L, EuroQol Group ﬁve-dimensional three-
level questionnaire; ICER, incremental cost-effectiveness ratio, IPC,
indwelling pleural catheter; IQR, interquartile range; LDH, Lactate
Dehydrogenase; LENT, pleural ﬂuid lactate dehydrogenase,
Eastern Cooperative Oncology Group (ECOG) performance score
(PS), neutrophil-to-lymphocyte ratio and tumour type; MCMC,
Markov Chain Monte Carlo; NT-proBNP, N-terminal pro-brain
natriuretic peptide; QALY, quality-adjusted life-year; TIME2, The
Second Therapeutic Intervention in Malignant Effusion; VAS,
visual analogue scale.
INTRODUCTION
Malignant pleural effusion is a common clinical entity
causing 42–77% of exudative effusions with more than
150 000 cases annually in the United States.1 Debilitat-
ing dyspnoea occurs in almost all patients with malig-
nant pleural effusion.2 The British Thoracic Society
currently recommends talc pleurodesis as ﬁrst-line
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SUMMARY AT A GLANCE
This is the ﬁrst cost-effectiveness analysis performed
alongside a randomized controlled trial comparing
indwelling pleural catheters with talc pleurodesis for
treating patients with malignant pleural effusions,
and it provides clinically relevant recommendations
regarding the cost-effective use of these therapies.
© 2016 The Authors
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treatment for patients with malignant pleural effusion.
Treatment with an indwelling pleural catheter (IPC) is
recommended as an alternative to talc pleurodesis only
in selected patients.3 Recently, The Second Therapeutic
Intervention in Malignant Effusion (TIME2) rando-
mized controlled trial compared the clinical efﬁcacy of
IPC versus talc pleurodesis in treating malignant pleu-
ral effusion.4 Both treatments resulted in signiﬁcant
improvement in the primary clinical outcome of sub-
jective patient dyspnoea, with IPC treatment also
resulting in decreased length of hospital stay and
decreased additional pleural procedures, but more
adverse events. A costing study performed alongside
the clinical trial showed no signiﬁcant difference in
overall costs between IPC and talc pleurodesis.5 IPC
was less costly when patient survival was limited
(<14 weeks), and more costly when patients were
assumed to require 2 h of nursing time per week. Using
quality of life data not previously published and com-
bining it with survival, we estimate the quality-adjusted
life-year of patients enrolled in the TIME2 trial and
report the incremental cost-effectiveness of IPC com-
pared with talc pleurodesis in patients with malignant
pleural effusion. Some of the results of this study have
been previously reported in the form of an abstract.6
METHODS
The design and methods of the TIME2 clinical trial and
costing study have been described in detail previ-
ously.4,5 The TIME2 is a multicentre, randomized con-
trolled trial comparing IPC with talc pleurodesis for
patients with malignant pleural effusion.4 Between
April 2007 and February 2011, seven centres across the
UK randomized 106 patients with conﬁrmed malignant
pleural effusion to either IPC (Rocket Medical,
Washington, UK) or talc (chest tube and talc slurry)
pleurodesis. Ethical and regulatory approval for the
study was obtained from the Milton Keynes Research
Ethics Committee before recruitment commenced
(REC number: 07/Q1603/2), and all patients provided
written informed consent prior to randomization. The
clinical trial is registered at www.isrctn.com (No.:
ISRCTN87514420). Most IPCs were inserted in the out-
patient setting while all talc pleurodesis was performed
in hospital. Patients with chylothorax, previous lobec-
tomy/pneumonectomy and attempted pleurodesis, and
pleural infection were excluded from the study. The
primary outcome measure was mean daily dyspnoea.
Secondary outcomes included: adverse events, fre-
quency of drainage, nights spent in hospital, all-cause
mortality and health-related quality of life assessed by
the EuroQol Group ﬁve-dimensional three-level ques-
tionnaire (EQ-5D-3L) (not previously reported).
Cost-effectiveness analysis
We conducted a cost-effectiveness analysis from the
perspective of the healthcare payer using costs and
quality of life data collected alongside the clinical trial.
The median survival in this patient population was
200 days (14% were alive at 1 year); therefore, no addi-
tional modelling of costs or quality of life beyond the
trial period was required. The cost-effectiveness analy-
sis was performed over the 1-year study period thus
discounting was not performed. Direct healthcare-
related costs were included in the analysis. Non-medical
costs (i.e. patient time and travel costs, as well as costs
related to lost productivity) were not included. Costs in
2011 UK pounds were inﬂated to 2014 values using the
UK Consumer Price Index (1.059).7 The Organisation for
Economic Co-operation and Development Purchasing
Power Parity Index (2013) was used to convert costs in
UK pounds to US dollars.8 Resource utilization and valu-
ation have been fully described previously.5
Survival and health-state preference
The EQ-5D-3L self-administered questionnaire evalu-
ates ﬁve patient attributes: mobility, self-care, usual
activity, pain/discomfort and anxiety/depression on a
three-point scale (no problem, some problems or
major problems). Patient responses to the EQ-5D-3L
produced scores that were then converted to utility
weights, ranging from 0 (death) to 1.0 (perfect health),
using the UK valuation set at each follow-up period.9
Negative values represent health states deemed worse
than death. Quality-adjusted life-years (QALYs) were
estimated by combining survival and utility scores
derived for each patient at baseline and each follow-up
period (2, 4, 6, 10, 14, 18, 22, 26, 39 and 52 weeks).
Statistical analysis
All analyses were calculated on an intention to treat
basis. We used non-parametric bootstrapping with 1000
replications to derive a 95% CI for the incremental mean
cost difference and mean QALY difference between the
two groups. For the bootstrap estimate, we used the per-
centile method. We randomly sampled with replace-
ment, generating 1000 random data sets. Difference in
mean costs and mean QALYs for each of the 1000 data
sets was calculated, ranked from lowest to highest and
the difference in mean cost and QALY for the 26th and
975th ordered values deﬁned the 95% CI.
Cost-effectiveness was calculated as the ratio of the
difference in costs between the IPC group and the talc
pleurodesis group divided by the difference in QALYs
gained between the two groups. Cost-effectiveness ratios
were computed for the 1-year trial period. To describe
the uncertainty in the estimates of cost-effectiveness, we
constructed cost-effectiveness acceptability curves, stat-
ing the probability that IPC was cost-effective at a given
willingness to pay threshold ($US50 000/QALY).
Missing data
Multiple imputation was used to estimate missing utility
scores and drainage volumes in patients alive during the
trial follow-up period in order to reduce potential bias
and increase precision.10 The method predicts missing
values by iteratively estimating regression models on
observed and imputed data.11 Multiple imputation was
conducted using PROC MI within SAS 9.2 (SAS Institute
Inc, Cary, North Carolina, USA), and the Markov Chain
Monte Carlo (MCMC) algorithm was chosen to draw
imputed values due to the non-monotone missing
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patterns. We generated 100 imputed data sets to ensure
that subsequent analyses produce a reliable and replica-
ble estimate of the posterior distribution around missing
values. The distribution of imputed data was compared
with the data before multiple imputation. Comparisons
of EQ-5D-3L data and drainage data before and after
multiple imputation are provided in Figures S1 and S2
(Supplementary Information). The proportion of missing
EQ-5D-3L data and drainage data is given in Table S1
(Supplementary Information). All statistical analyses
were performed using Stata 11.2 (StataCorp LP, College
Station, Texas, USA).
Sensitivity analysis
In our previously published costing study, a signiﬁcant
change in the mean cost difference between the IPC and
talc pleurodesis groups was seen with patient survival (>
and <14 weeks), and by modelling nursing time required
for IPC drainage; therefore, this sensitivity analysis was
also performed in the cost-effectiveness analysis.
RESULTS
Baseline characteristics and mortality between the two
groups in the clinical trial were similar (Table 1).4
Quality of life
The EQ-5D-3L utility scores were missing in 2%, 11%,
24% and 28% of IPC patients and 2%, 22%, 25% and
41% of talc patients at baseline, 14 weeks, 26 weeks
and 1 year, respectively (Table S1, Supplementary
Information). Mean (SD) utility scores were similar at
baseline, 0.59 (0.17) in the IPC group and 0.61 (0.17) in
the talc group (P = 0.65), and during follow-up, 0.79
(0.16) versus 0.67 (0.32) (P = 0.30) for the IPC and talc
groups, respectively (Fig. 1, Table 2). Individual
responses to the ﬁve attributes evaluated in the EQ-5D-
3L questionnaire are provided in Tables S2 and S3
(Supplementary Information). At 1 year, the mean
QALYs gained (SD) in the IPC and talc groups were
0.35 (0.296) and 0.33 (0.303), with a mean QALY differ-
ence of 0.026 (95% CI: −0.09 to 0.13; P-value = 0.64)
(Table 3).
Cost-effectiveness
Mean total cost (SD) for managing patients with IPC
compared with talc did not differ signiﬁcantly. The esti-
mated incremental cost-effectiveness ratio (ICER) for
IPC as compared with talc during the 52 weeks follow-
ing initiation of treatment was $US10 870 per QALY
gained (Table 3). The cost-effectiveness plane plots all
the 1000 bootstrapped estimates of incremental costs
and QALYs (ICERs) between the IPC and talc groups.
Point estimates are situated in all four quadrants of the
cost-effectiveness plane, reﬂecting uncertainty around
the baseline cost-effectiveness ratio (Fig. 2). At a
threshold of £30 000 ($US42 947) per QALY, the proba-
bility that IPC is cost-effective compared with talc is
approximately 65% (Fig. 3).
Table 1 Baseline demographic data and mortality for 106 patients with malignant pleural effusion
IPC Talc
Number 52 54
Age, mean (SD), years 67 (11) 67 (12)
Male:female (%male) 23:29 (44) 23:31 (43)
Type of malignancy
Breast 16 11
Lung 9 16
Mesothelioma 6 5
Other† 21 21
VAS dyspnoea, mean (SD), mm 62 (22) 55 (26)
VAS chest pain, mean (SD), mm 29 (30) 22 (29)
Size of effusion on chest radiograph,
% hemithorax (SD)
51 (23) 49 (25)
EORTC QLQ-C30
Global health status % (SD) 37 (23) 37 (20)
Inpatient:outpatient at enrolment (%
inpatient)
19:33 (35) 22:31 (42)
Mortality
Median survival, days (IQR) 153 (73–288) 200 (39–392)
Adapted from Davies et al.,4 with permission.
†Other malignancies were colorectal (four IPC:three talc), ovarian (two IPC:ﬁve talc), adenocarcinoma of unknown primary (four IPC:
two talc), renal (three IPC:two talc), sarcoma (one IPC:two talc), thymoma (one IPC:one talc), oesophageal (two IPC), peritoneal (one
IPC:one talc), prostate (one IPC), ampullary (one IPC), leiomyosarcoma (one IPC), melanoma (one talc), myeloma (one talc), nasopha-
ryngeal (one talc) and unknown (one IPC:one talc). One patient in the talc group died prior to enrolment so no demographic data was
available.
EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire – Core Questionnaire;
IPC, indwelling pleural catheter; IQR, interquartile range; SD, standard deviation; VAS, visual analogue scale.
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Sensitivity analysis
In patients with limited survival (<14 weeks), mean total
cost was lower in the IPC group than in the talc group,
$US2693 (2095) versus $US4563 (2975), resulting in a
signiﬁcant mean difference of −$US1870 (95% CI: −3358
to −176). The QALYs gained in the IPC and talc groups
were similar with a mean QALY difference of 0.024 (95%
CI: −0.01 to 0.05) (Table 3). In this subgroup of patients,
the probability that IPC is cost-effective compared with
talc at a threshold of £30 000 ($US42 947) per QALY
exceeds 95% (Figs S3, S4 (Supplementary Information)).
When patients in the IPC group were assumed to
require 2 h of nursing care per week, the mean total
cost was higher in the IPC group than in the talc group,
$US6416 (5993) versus $US4375 (4242), resulting in a
signiﬁcant mean difference of 2041 (95% CI: 117–4280).
Under this scenario, the estimated ICER was $US77 213
per QALY gained (Table 3), and the probability that IPC
is cost-effective compared with talc is approximately
35% at a threshold of £30 000 ($US42 947) per QALY
(Figs S5, S6 (Supplementary Information)) In patients
with both limited survival (<14 weeks) and assumed to
require 2 h of nursing care per week, the mean total
cost did not signiﬁcantly differ between the IPC and talc
groups (Table 3). Under this scenario, the probability of
IPC being cost-effective compared with talc at a thresh-
old of £30 000 ($US42 947) per QALY exceeds 95% (Figs
S7, S8 (Supplementary Information)).
DISCUSSION
Our study is the ﬁrst cost-effectiveness analysis to com-
pare IPC with talc pleurodesis in the treatment of
malignant pleural effusion alongside a randomized
controlled trial. The baseline ICER for IPC compared
with talc pleurodesis is favourable, but a signiﬁcant
degree of uncertainty exists around this estimate. This
ﬁnding is not unexpected given that, on average, the
difference between IPC and talc pleurodesis with
respect to costs, survival and QALYs is not signiﬁcant.
Using the cost-effectiveness acceptability curve to illus-
trate the uncertainty around the incremental cost-
effectiveness estimate, it is clear that the probability of
IPC being cost-effective compared with talc pleurodesis
increases as the willingness to pay for health gains
increases. However, beyond a threshold of £30 000
($US42 947) per QALY, the probability that IPC
remains cost-effective relative to talc pleurodesis never
exceeds 65%.
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Figure 1 Box and whisker plots
of indwelling pleural catheter (IPC)
and talc EQ-5D-3L utility scores at
various follow-up intervals. The
line within each box represents
the median. The top and bottom
of the boxes represents the 75th
and 25th percentiles. The top and
bottom of the whiskers represents
the 95th and 5th percentiles.
Utility scores were similar at
baseline and throughout the trial
follow-up period between the
groups. Each individual group’s
utility scores did not change
signiﬁcantly during the trial
follow-up period ( , baseline; ,
week 6; , week 14; , 6 months;
, 1 year).
Table 2 Quality of life as measured by the EQ-5D-3L utility index in the IPC and talc groups
Time from randomization
IPC mean
EQ-5D-3L (SD) Alive IPC patients (n)
Talc mean
EQ-5D-3L‡ (SD) Alive talc patients (n)
Baseline 0.594 (0.17) 52 0.608 (0.17) 54
Week 2 0.629 (0.25) 51 0.656 (0.20) 45
Week 4 0.681 (0.16) 48 0.668 (0.22) 41
Week 6 0.681 (0.21) 43 0.659 (0.22) 40
Week 10 0.679 (0.22) 39 0.702 (0.20) 35
Week 14 0.684 (0.20) 36 0.679(0.16) 32
Week 18 0.699 (0.20) 35 0.738 (0.20) 32
Week 22 0.706 (0.20) 30 0.659 (0.21) 31
Week 26 0.727 (0.18) 29 0.714 (0.17) 28
9 months 0.683 (0.23) 23 0.717 (0.22) 22
1 year 0.788 (0.16) 18 0.674 (0.32) 18
EQ-5D-3L, EuroQol Group ﬁve-dimensional three-level questionnaire; IPC, indwelling pleural catheter; SD, standard deviation.
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As would be expected, if nursing time required to
drain the IPC is assumed to be 2 h per week (in the
TIME2 trial, patients and caregivers drained the IPC
without nurse assistance), then IPC is not considered to
be cost-effective, particularly at a willingness to pay
threshold of £30 000 ($US42 947) per QALY (Figs S5, S6
(Supplementary Information)). Interestingly, and similar
to other studies which have performed decision model-
ling around the cost-effectiveness of IPC versus talc
pleurodesis,12,13 our study suggests that IPC is cost-
effective relative to talc pleurodesis in patients with lim-
ited survival (<14 weeks). For those with both limited
survival and assumed nursing care requirements, IPC
remains favourable compared with talc, and the
probability of IPC being cost-effective at any willingness
to pay exceeds 95% (Figs S7, S8 (Supplementary
Information)).
The results of this cost-effectiveness analysis support
the recommendations made in our previously reported
costing study.5 Either IPC or talc pleurodesis may be
used as a ﬁrst-line option in the treatment of malignant
pleural effusion after considering patient preferences
based on the risks and beneﬁts of both treatments. All
other factors being equal, we recommend the follow-
ing: (i) IPC should be considered the most cost-
effective treatment when expected patient survival is
<14 weeks, regardless of intensity of nursing care
required for drainage and (ii) talc pleurodesis should
Table 3 Total costs (US $US 2014) and QALYs, mean difference for costs and QALYs, and ICER for all patients, those
surviving <14 weeks and those requiring 2-h nursing time
Variable
IPC
Mean (SD)
Talc
Mean (SD)
Mean difference
Mean (95% CI)
P-
value
All patients Total costs ($US) 4591 (5300) 4303 (4107) 287 (−1428 to
2430)
0.77
QALY gained 0.354
(0.296)
0.328
(0.303)
0.026 (−0.085 to
0.134)
0.64
Mean ICER for IPC
(95% CI)
$US10 870/QALY
Survival < 14 weeks† Total costs ($US) 2693 (2095) 4563 (2975) −1870 (−3358 to
−176)
0.04
QALY gained 0.064
(0.052)
0.041
(0.039)
0.024 (−0.005 to
0.05)
0.13
Mean ICER for IPC
(95% CI)
−$US79 303/QALY
Nursing care = 2 h per week Total costs ($US) 6416 (5993) 4375 (4242) 2041 (117 to
4280)
0.04
QALY gained 0.354
(0.296)
0.328
(0.303)
0.026 (−0.085 to
0.134)
0.64
Mean ICER for IPC
(95% CI)
$US77 213/QALY
Survival < 14 weeks and nursing
care = 2 h per week
Total costs ($US) 3323 (2141) 4642 (2999) −1317 (−3008 to
238)
0.18
QALY gained 0.064
(0.052)
0.041
(0.039)
0.024 (−0.005 to
0.05)
0.13
Mean ICER for IPC
(95% CI)
−$US55 889/QALY
Survival > 14 weeks Total costs ($US) 5511 (6116) 4524 (4788) 987 (−1411 to
3630)
0.48
QALY gained 0.495
(0.261)
0.539
(0.226)
−0.044 (−0.159 to
0.076)
0.48
Mean ICER for IPC
(95% CI)
−$US22 299/QALY
†Sixteen (31%) IPC patients and 22 (41%) talc patients survived <14 weeks. The cost-effectiveness plane and cost-effectiveness
acceptability curve for patients with survival >14 weeks are shown in Figures S9 and S10 (Supplementary Information). Values also
expressed in 2014 UK pounds are shown in Table S4 (Supplementary Information).
CI, conﬁdence interval; ICER, incremental cost-effectiveness ratio; IPC, indwelling pleural catheter; QALY, quality-adjusted life-year;
SD, standard deviation.
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be considered the most cost-effective treatment when
patients will require two or more hours of nursing care
per week for drainage and catheter care.
Previous cost-effectiveness analyses using observa-
tional data suggest the cost-effectiveness of IPC com-
pared with talc depends on patient survival12,13;
however, predicting survival in those with malignant
pleural effusion is challenging. Lumachi et al. found
that survival after talc pleurodesis was independent of
age, gender, type of malignancy and amount of pleural
ﬂuid; however, this study was likely underpowered.14
More recently, Clive et al. demonstrated effusion size,
ECOG performance score, pleural ﬂuid LDH, serum
neutrophil-to-lymphocyte ratio, serum NT-proBNP and
malignant cell type to be independently associated with
survival.15 A predictive model using some of these
variables (LENT score) divided patients into low-,
moderate- and high-risk groups with median survivals
of 319, 130 and 44 days, respectively. The LENT score
was subsequently validated in a separate patient
cohort. This prognostication tool may help guide deci-
sions regarding treatment in patients with malignant
pleural effusion. In the TIME2 trial, patients were
included in the trial if expected survival was more than
3 months based on ECOG score.4 Despite this inten-
tion, there were still a signiﬁcant proportion of patients
who survived <3 months and in this group, IPC was
found to be a cost-effective management strategy.
Several limitations exist for this study. The sample size
was powered to detect clinically important outcomes, but
not necessarily differences in cost-effectiveness. Our study
still provides much needed information regarding the
quality of life, survival, costs and cost-effectiveness of
these two therapies. Some resource use and costs may
have been missed such as those for oxygen and morphine
for end-stage dyspnoea, and non-intervention-related hos-
pitalizations. However, the impact of these variables on
overall costs is unlikely to be signiﬁcant and did not likely
differ between the two groups. The study perspective was
limited to that of the healthcare payer and therefore did
not include time costs of patients, caregiver burden costs,
costs associated with productivity loss and travel costs.
This may be important as our study assumed that the
patient and family would be performing the catheter
drainage and dressing changes. Furthermore, this may
also be important in more rural jurisdictions where
patient travel time to clinical care is increased. The effect
on costs from increased home nursing care for IPC drain-
age was modelled in the sensitivity analysis, as home
nursing care was not a routine part of care during the
trial. One might expect that patients requiring increased
nursing care at home would have differences in quality of
life compared with those patients who are more inde-
pendent, which could affect the incremental cost-
effectiveness of IPC compared with talc. Finally, the utili-
zation and valuation of resources required for IPC and talc
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Figure 2 Cost-effectiveness plane for
all patients. Thousand bootstrapped
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and quality-adjusted life-years
(QALYs) (incremental cost-
effectiveness ratios, ICERs) between
the indwelling pleural catheter (IPC)
and talc groups are plotted. In the left
upper quadrant of the plane, point
estimates reﬂect when IPC is more
costly and less effective (mean
negative QALY difference) than talc
(i.e. inferior strategy). In the right
lower quadrant, point estimates
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effective than talc (i.e. dominant
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IPC is either more effective and more
costly than talc or less effective and
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Point estimates are situated in all four
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effective compared with talc is plotted against the willingness to
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probability of IPC being cost-effective compared to talc
increases. At a threshold of £30 000 ($US42 947) per quality-
adjusted life-year (QALY), the probability of IPC being cost-
effective compared with talc is 65%.
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may differ between countries. Therefore, our recommen-
dations may not be easily generalizable outside of the UK
where the study was performed.
In conclusion, the cost-effectiveness of IPC is favour-
able when compared with talc pleurodesis, although
substantial uncertainty exists around this estimate. In
patients with limited survival, IPC is less costly and as a
result, cost-effective compared with talc pleurodesis.
We recommend that either IPC or talc pleurodesis be
considered as a ﬁrst-line option in the treatment of
malignant pleural effusion in patients without a history
of prior pleurodesis.
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